Sandbox/AIRSG
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Definition
Aortic insufficiency is the
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
- [[
Common Causes
- [[
- [[
- [[
- [[
Management
Shown below is an algorithm summarizing the approach to aortic insufficiency [1][2]
Characterize the symptoms: ❑ Most patients are asymptomatic ❑ Dyspnea on exertion ❑ Exertional dizziness ❑ Exertional angina ❑ Syncope ❑ Chest pain ❑ Palpitations | |||||||||||||||||||||||||||||||||||||||||||||||||
Inquire about past medical history: ❑ Previously healthy ❑ Cardiac disease: ❑ Rheumatic fever ❑ Pulmonary disease | |||||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient: ❑ Heart rate ❑ Cardiac palpation
❑ Cardiac auscultation
| |||||||||||||||||||||||||||||||||||||||||||||||||
Order imaging studies: ❑ Order an echocardiography, assess:
❑ Order a CXR, look for:
❑ Order a ECG, look for:
| |||||||||||||||||||||||||||||||||||||||||||||||||
Interpret results from echo | |||||||||||||||||||||||||||||||||||||||||||||||||
Mild to moderate stenosis (Stage B) Mild: ❑ Valve area 1.5-2.5 cm² ❑ Pressure gradient ≤ 25 mmHg Moderate: ❑ Valve area 1.0-1.5 cm² ❑ Pressure gradient 25-40 mmHg | Severe stenosis ❑ Valve area ≤ 1.0 cm² ❑ Pressure gradient ≥ 40 mmHg | ||||||||||||||||||||||||||||||||||||||||||||||||
❑ Normal valve ❑ Bicuspid valve ❑ Sclerotic valve | Perform a periodic echocardiogram (Class I; Level of Evidence: B) ❑ Every 3 -5 yrs for mild stenosis ❑ Every 1 - 2 yrs for moderate stenosis | Patient asymptomatic (Stage C) | Patient symptomatic (Stage D) | ||||||||||||||||||||||||||||||||||||||||||||||
❑ Control hypertension (Class I; Level of Evidence: B) | Normal LVEF (Stage C1) | LVEF < 50% (Stage C2) | High gradient (ΔP ≥ 40 mmHg) (Stage D1) | ||||||||||||||||||||||||||||||||||||||||||||||
Perform a periodic echocardiogram every 6 - 12 months (Class I; Level of Evidence: B) | Schedule for AVR (Class I; Level of Evidence: A) | Schedule for AVR (Class IIa; Level of Evidence: B-C) | |||||||||||||||||||||||||||||||||||||||||||||||
If aortic velocity ≥ 5 m/s or decrease in exercise tolerance: ❑ Schedule for AVR (Class IIa; Level of Evidence: B) | |||||||||||||||||||||||||||||||||||||||||||||||||
LVH: Left ventricle hypertrophy; CXR: Chest x-ray; ECG: Electrocardiogram; LBBB: Left bundle branch block; AF: Atrial fibrillation; AVR: Aortic valve replacement; VHD: Valve heart disease; TAVR: Transcatheter aortic valve replacement
Choice of intervention
Shown below is an algorithm summarizing the choice of the intervention to aortic stenosis [1]
Patient scheduled for AVR | |||||||||||||||||||||||||||||||||
High risk[3]
❑ STS Score[4] > 10 ❑ EuroScore[5] > 20 | Low to moderate risk[3]
❑ STS Score[4] < 10 ❑ EuroScore[5] < 20 | ||||||||||||||||||||||||||||||||
❑ A multidisciplinary group of physicians with expertise in VHD, cardiac imaging, interventional cardiology, cardiac anesthesia, and cardiac surgery should decide intervention (Surgical AVR or TAVR) (Class I; Level of Evidence: C) ❑ Schedule for TAVR (Class IIa; Level of Evidence: B)[1] [6] | ❑ Schedule for surgical AVR (Class I; Level of Evidence: A) | ||||||||||||||||||||||||||||||||
STS: Society of Thoracic Surgeons
Type of valve and anticoagulation therapy
❑ Age of patient? ❑ Anti-coagulation contraindications? | |||||||||||||||||||||||||||||||||
❑ Patients ≤ 70 years old (Class IIa; Level of Evidence: B) | ❑ Patients with anticoagulant therapy contraindications (Class I; Level of Evidence: C) ❑ Patients ≥ 70 years old (Class IIa; Level of Evidence: B) | ||||||||||||||||||||||||||||||||
Mechanical Prosthesis | Bioprosthesis | ||||||||||||||||||||||||||||||||
Patient with risk factors | Patient without risk factors | AVR | TAVR | ||||||||||||||||||||||||||||||
❑ Either a bioprosthetic or mechanical valve is reasonable in patients between 60 and 70 years of age. (Class IIa; Level of Evidence: B).
Do's
❑ Give ACE inhibitors to control hypertension in patients with asymptomatic aortic stenosis. [7]
❑ Exercise testing in asymptomatic patients with AS may be considered to elicit exercise-induced symptoms and abnormal blood pressure responses (Class IIb; Level of Evidence: B).
❑ Dobutamine stress echocardiography is reasonable to evaluate patients with low-flow/low-gradient AS and LV dysfunction (Stage D3) (Class IIa; Level of Evidence: B)
❑ Aortic balloon valvotomy might be reasonable as a bridge to surgery in hemodynamically unstable adult patients with AS who are at high risk for AVR or cannot be performed because of serious comorbid conditions.(Class IIb; Level of Evidence: C).
Don'ts
❑ Do not perform a stress test in a symptomatic patient with stage D aortic stenosis (Class III; Level of Evidence: B).
❑ Do not give statins to prevent hemodynamic progression in patients with mild to moderate calcific aortic valve disease (Class III; Level of Evidence: A).
❑ TAVR is not recommended in patients in whom existing comorbidities would preclude the expected benefit from correction of AS (Class III; Level of Evidence: B)
❑ Do not give vasodilators to patients with severe AS as they may cause severe hypotension.
❑ Endocarditis prophylaxis is not indicated in patients with AR. [8]
References
- ↑ 1.0 1.1 1.2 "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary". Retrieved 4 March 2014.
- ↑ Bonow, R. O.; Carabello, B. A.; Chatterjee, K.; de Leon, A. C.; Faxon, D. P.; Freed, M. D.; Gaasch, W. H.; Lytle, B. W.; Nishimura, R. A.; O'Gara, P. T.; O'Rourke, R. A.; Otto, C. M.; Shah, P. M.; Shanewise, J. S. (2008). "2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–e661. doi:10.1161/CIRCULATIONAHA.108.190748. ISSN 0009-7322.
- ↑ 3.0 3.1 Ben-Dor, I.; Pichard, A. D.; Gonzalez, M. A.; Weissman, G.; Li, Y.; Goldstein, S. A.; Okubagzi, P.; Syed, A. I.; Maluenda, G.; Collins, S. D.; Delhaye, C.; Wakabayashi, K.; Gaglia, M. A.; Torguson, R.; Xue, Z.; Satler, L. F.; Suddath, W. O.; Kent, K. M.; Lindsay, J.; Waksman, R. (2010). "Correlates and Causes of Death in Patients With Severe Symptomatic Aortic Stenosis Who Are Not Eligible to Participate in a Clinical Trial of Transcatheter Aortic Valve Implantation". Circulation. 122 (11_suppl_1): S37–S42. doi:10.1161/CIRCULATIONAHA.109.926873. ISSN 0009-7322.
- ↑ 4.0 4.1 "Online STS Risk Calculator". Retrieved 7 March 2014.
- ↑ 5.0 5.1 "http://www.euroscore.org/calc.html". Retrieved 7 March 2014. External link in
|title=
(help) - ↑ Smith, Craig R.; Leon, Martin B.; Mack, Michael J.; Miller, D. Craig; Moses, Jeffrey W.; Svensson, Lars G.; Tuzcu, E. Murat; Webb, John G.; Fontana, Gregory P.; Makkar, Raj R.; Williams, Mathew; Dewey, Todd; Kapadia, Samir; Babaliaros, Vasilis; Thourani, Vinod H.; Corso, Paul; Pichard, Augusto D.; Bavaria, Joseph E.; Herrmann, Howard C.; Akin, Jodi J.; Anderson, William N.; Wang, Duolao; Pocock, Stuart J. (2011). "Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients". New England Journal of Medicine. 364 (23): 2187–2198. doi:10.1056/NEJMoa1103510. ISSN 0028-4793.
- ↑ Chambers, J. (2005). "The left ventricle in aortic stenosis: evidence for the use of ACE inhibitors". Heart. 92 (3): 420–423. doi:10.1136/hrt.2005.074112. ISSN 1355-6037.
- ↑ Bonow, RO.; Carabello, BA.; Chatterjee, K.; de Leon, AC.; Faxon, DP.; Freed, MD.; Gaasch, WH.; Lytle, BW.; Nishimura, RA. (2008). "2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172. Unknown parameter
|month=
ignored (help)